On the other hand, these defects can prompt prostate cancer cells to activate compensatory signaling pathways, such as the PI3K/AKT/mechanistic target of rapamycin (mTOR) or mitogen-activated protein kinase (MAPK) pathways, to sustain cell survival and progression [35]. This evidence concerns the gene AKT1 and prostate carcinoma.